This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Position statements: ESPGHAN

The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) is a European medical association focused on the gastrointestinal health of children1

The ESPGHAN IBD Porto group is a group of experts who generate collaborative international research on the diagnosis and management of IBD in children2

The ESPGHAN IBD Porto group released an updated position statement in 2019 that supports the use of INFLECTRA® (CT-P13*/infliximab) in appropriate paediatric patients with IBD3

“There are sufficient data (by extrapolation from different indications, adult data and limited paediatric data) to state that in children with IBD who are indicated for infliximab treatment, CT-P13 is an efficacious alternative to the originator infliximab for induction, and maintenance, of remission”3“A switch from the originator infliximab to CT-P13 may be considered in children with IBD in clinical remission, following at least 3 induction infusions”3
CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.IBD, Inflammatory bowel disease.

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:ESPGHAN web site. What we do. Available at: https://www.espghan.org/. Accessed May 2023.ESPGHAN web site. Paediatric IBD Porto & Interest Group. Available at: https://www.espghan.org/our-organisation/council-and-committees/gastroenterology-committee. Accessed May 2023.de Ridder L, et al. J Pediatr Gastroenterol Nutr 2019;68(1):144-53.
Position statements
Support & Resources

Pfizer has a range of resources available to support you and your patients

 Explore Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0146 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
PP-UNP-IRL-0176. January 2023